Strong Prescription Growth and Competitive Advantage Drive Buy Rating for Arcutis Biotherapeutics
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...
ACADIA Pharmaceuticals: Untapped Potential with Financial Stability and Strategic Growth Opportunities
Analyst Marc Goodman of Leerink Partners maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), retaining the price target ...
Alta Mesa Investors Reach Partial Settlements as Trial Starts
Alta Mesa Resources Inc. investors have reached class settlements worth more than $11 million with several defendants as a trial begins over the blank-check merger that brought the now-defunct energy ...
Le Lézard23h
State-of-the-science webinar will explore narcolepsy and hypersomnia
The Sleep Research Society Foundation is hosting a state-of-the-science webinar, "Lessons Learned from Central Disorders of Hypersomnolence and Future Directions," Monday, Dec. 2, from 9:30 a.m. to 11 ...